← Back to Search

Small Molecule Drug

Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Hossein Borghaei, DO
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights

Study Summary

This trial is studying a new lung cancer drug to see if it shrinks tumors before surgery. Doctors will enroll 25 patients who have not had lung cancer treatment before and are healthy enough for surgery.

Eligible Conditions
  • Non-Small Cell Lung Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major pathologic response
Secondary outcome measures
Determine the safety, feasibility and tolerability of neoadjuvant sotorasib therapy in patients with surgically resectable KRAS G12C mutant NSCLC

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
231 Previous Clinical Trials
38,336 Total Patients Enrolled
Hossein Borghaei, DOPrincipal InvestigatorFox Chase Cancer Center
3 Previous Clinical Trials
93 Total Patients Enrolled
~0 spots leftby Jun 2025